Document is current
Any future updates will be listed below
-
Authors
Song, Yun
Straker, Richard J. III
Xu, Xiaowei
Elder, David E.
Gimotty, Phyllis A.
Huang, Alexander C.
Mitchell, Tara C.
Amaravadi, Ravi K.
Schuchter, Lynn M.
Karakousis, Giorgos C.
- License Information
-
More Information
Article History
Received: 13 September 2019
First Online: 2 January 2020
Disclosure
: Dr. Karakousis is the Principal Investigator in an investigator-initiated clinical trial of neoadjuvant pembrolizumab in patients diagnosed with clinical stage IIB/C melanoma (NCT03757689), sponsored by Merck Sharp & Dohme Corp. Dr. Mitchell has had advisory roles with Merck, Bristol-Myers Squibb, Incyte, and Array BioPharma. Dr. Schuchter has participated in clinical trial activities with Bristol-Myers Squibb and Merck. Yun Song, Richard J. Straker III, Xiaowei Xu, David E. Elder, Phyllis A. Gimotty, Alexander C. Huang, and Ravi K. Amaravadi have declared no relevant conflicts of interest.
